Man Group’s Xeris Biopharma Holdings XERS Stock Holding History

Man Group’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.6M	Buy	276,422 +228,647	+479%	+$1.52M	﹤0.01%	1658
2025 Q4	$375K	Buy	+47,775	New	+$376K	﹤0.01%	1964
2025 Q3	–	Sell	-130,849	Closed	-$611K	–	2506
2025 Q2	$611K	Sell	130,849 -44,398	-25%	-$203K	﹤0.01%	1769
2025 Q1	$962K	Buy	+175,247	New	+$707K	﹤0.01%	1592
2024 Q2	–	Sell	-199,023	Closed	-$440K	–	2303
2024 Q1	$440K	Buy	+199,023	New	+$515K	﹤0.01%	1823
2022 Q2	–	Sell	-439,782	Closed	-$1.13M	–	2443
2022 Q1	$1.13M	Sell	439,782 -1,218,658	-73%	-$2.98M	﹤0.01%	1337
2021 Q4	$4.86M	Buy	1,658,440 +1,622,040	+4,456%	+$3.5M	0.02%	884
2021 Q3	$89K	Buy	+36,400	New	+$106K	﹤0.01%	1817

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Man Group's XERS Position: Q1 2026 in Review

Man Group increased its Xeris Biopharma Holdings (XERS) stake by 479% in Q1 2026, buying an estimated $1.52M and bringing the position to 276,422 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1658.

Man Group first reported a position in XERS in Q3 2021 and has held it in 8 quarters since. The position peaked at $4.86M in Q4 2021. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Man Group held 276,422 shares of Xeris Biopharma Holdings worth $1.6M as of Q1 2026.
Man Group bought 228,647 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.52M.
Xeris Biopharma Holdings made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1658 holding.
Man Group first reported a position in Xeris Biopharma Holdings in Q3 2021 and has held it in 8 quarters since.
Man Group's Xeris Biopharma Holdings position peaked at $4.86M in Q4 2021.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.